CAS 54827-14-4: Ganglioside GM3

Ganglioside GM3 (sodium salt) has a core disaccharide structure (Galβ1,4Glc) with sialic acid linked α2,3 to the galactose residue and ceramide linked β to position 1 on the reducing terminal glucose residue (Ledeen, 2009). Ganglioside GM3 is strongly associated with human tumors, such as: lung, brain and melanomas, where it is over expressed. It is seen as a possible tumor-associated carbohydrate antigen for cancer immunotherapy (Changping, 2019). GM3 ganglioside is implicated in various other diseases involving chronic inflammation, such as: insulin resistance, leptin resistance, T-cell function and immune disorders (e.g., allergic asthma). It has also been shown to play an essential role in murine and human auditory systems, and a common pathological feature of GM3S deficiency is deafness (Inokuchi, 2018).

Applications Monosialoganglioside GM3 can have anti-tumor effects by regulating cell apoptosis, angiogenesis. Monosialoganglioside GM3 can also regulate peripheral insulin receptor signaling and increases in GM3 in adipose tissue of obese humans may contribute to insulin resistance. References Zhu, Y., et al.: Zhongliu Fangzhi Yanjiu, 42, 450 (2015); Herzer, S., et al.: Diabetes, 64, 3363 (2015); Wentworth, J., et al.: ?Int. J. Obes., 40, 706 (2016)

Ganglioside GM3 (ammonium salt) has a core disaccharide structure (Galβ1,4Glc) with sialic acid linked a2,3 to the galactose residue and ceramide linked β to position 1 on the reducing terminal glucose residue (Ledeen, 2009). Ganglioside GM3 is strongly associated with human tumors, such as, lung, brain and melanomas where it is over expressed. It is seen as a possible tumor-associated carbohydrate antigen for cancer immunotherapy (Changping, 2019). GM3 ganlioside is implicated in various other diseases involving chronic inflammation, such as, insulin resistance, leptin resistance, T-cell function and immune disorders (e.g. allergic asthma). GM3 ganglioside has also been shown to play an essential role in murine and human auditory systems, and a common pathological feature of GM3S deficiency is deafness (Inokuchi, 2018).

GM3 ganglioside inhibits tumor growth, angiogenesis, and HUVEC migration by disrupting cell signaling and insulin receptors.